Take­da end­ing dis­cov­ery, pre­clin­i­cal work in AAV gene ther­a­py, rare hema­tol­ogy

Take­da told em­ploy­ees re­cent­ly it is end­ing dis­cov­ery and pre­clin­i­cal work in AAV gene ther­a­py as well as re­search and pre­clin­i­cal work on rare hema­tol­ogy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER